BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines GAAP SG&A Expense as % of Product Sales by Year
GAAP SG&A Expense as % of Product Sales (%) (%)
BeOne Medicines GAAP SG&A Expense as % of Product Sales: 39.0% in FY2025, down 9.0 pts from a year earlier.
Latest, FY2025
39.0%
Period ended Dec 31, 2025
Change on a year earlier
-9.0 pts
48.0% in FY2024
History
3 years
Since FY2023
Sources
2
Documents cited below
Where the FY2025 figure comes from
“SG&A expenses as a percentage of product sales were 38% and 39% for the fourth quarter and full year of 2025, compared to 45% and 48%”
Source: Form 8-K (filed 2026-02-26) ↗
Reported in Form 8-K EX-99.1 Earnings Releases.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | GAAP SG&A Expense as % of Product Sales (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 39.0% | -9.0 pts | Form 8-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 48.0% | -21.0 pts | Form 8-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 69.0% | – | Form 8-K (filed 2025-02-27) ↗ |
Cite this data
StockData. (2026). BeOne Medicines GAAP SG&A Expense as % of Product Sales (%), annual FY2023–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/sga-pct-prod-rev
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.